Such findings highlight the importance and possible suitability of MUC16 as a CAR-T therapy target antigen; however, hurdles must be recognized and arduously overcome to better the therapeutic responses achieved in ovarian cancer patients. The gene discussed is MUC16; the disease is ovarian cancer.